Patent US4440740A successfully refreshed from Google Patents.
US4440740A
Expired / Lapsed
US
⏱️ 0.0 years remaining
α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption
Assignee: Merck and Co Inc
•
Filing: 1982-04-26
•
Granted: 1984-04-03
•
Expires: 2002-04-26
Abstract
Abstract A method and drug form enhancing the absorption of a rectally or orally administered drug from the rectal compartment into the blood stream of a warm blooded animal. The method includes the steps of preparing a drug form capable of being rectally and orally administered. The drug form comprises a therapeutically effective unit dosage amount of a selected drug of the type which is capable of being absorbed into the blood stream from the gastrointestinal area and an alpha -keto aldehyde or salts thereof being present in the drug form in a sufficient amount to be effective in enhancing the drug absorption rate, when administering the drug form to warm blooded animals.
Inventors
- 👤 Joseph A. Fix
- 👤 Stefano A. Pogany
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 14:39
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/06; A61K47/08
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
193 words
A method for enhancing the absorption of an orally or rectally administered drug from the gastrointestinal compartment into the bloodstream, said method comprising the steps of preparing a drug form capable of being orally or rectally administered, said drug form comprising a therapeutically effective dosage amount of a drug capable of being absorbed into the bloodstream from the gastrointestinal compartment said drug comprising antibiotics, xanthines, anticancer agents, polypeptides, antiarthritic, cardiovascular agents, antidiabetics, antiulcers, antifungals, antinauseants, sedatives, diuretics, antihypertensives, anti-inflammatories, anthelmintics, antiviral agents, radio-opaques and radionuclide diagnostic agents, polynucleotides, or anti-Parkison agents and an α-keto aldehyde of the formula: ##STR3## wherein R is hydroxy, phenyl, substituted phenyl or lower alkyl (C 1-5 ) and wherein the substituents on the substituted phenyl radical can be halo, lower alkyl, (C 1-5 ) or hydroxy and the pharmaceutically acceptable acid addition salts when R is hydroxy or a pharmaceutically acceptable salt thereof as adjuvants, said adjuvant being present in said drug in a sufficient amount to be effective in enhancing said absorption and the percentage of the drug to drug plus adjuvant is 5% to 50% by weight and administering said drug form into said gastrointestinal compartment.
Claim 2
Independent Claim
193 words
A method for enhancing the absorption of an orally or rectally administered drug from the gastrointestinal compartment into the bloodstream, said method comprising the steps of preparing a drug form capable of being orally or rectally administered, said drug form comprising a therapeutically effective dosage amount of a drug capable of being absorbed into the bloodstream from the gastrointestinal compartment said drug comprising antibiotics, xanthines, anticancer agents, polypeptides, antiarthritic, cardiovascular agents, antidiabetics, antiulcers, antifungals, antinauseants, sedatives, diuretics, antihypertensives, anti-inflammatories, anthelmintics, antiviral agents, radio-opaques and radionuclide diagnostic agents, polynucleotides, or anti-Parkison agents and an α-keto aldehyde of the formula: ##STR3## wherein R is hydroxy, phenyl, substituted phenyl or lower alkyl (C 1-5 ) and wherein the substituents on the substituted phenyl radical can be halo, lower alkyl, (C 1-5 ) or hydroxy and the pharmaceutically acceptable acid addition salts when R is hydroxy or a pharmaceutically acceptable salt thereof as adjuvants, said adjuvant being present in said drug in a sufficient amount to be effective in enhancing said absorption and the percentage of the drug to drug plus adjuvant is 5% to 50% by weight and administering said drug form into said gastrointestinal compartment.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein the drug comprises an antibiotic.
Claim 4
Dependent Claim
26 words
The method of claim 1 wherein said adjuvant comprises an α-keto aldehyde comprising glyoxylic acid, phenylglyoxal or methylglyoxal or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim
64 words
The method of claim 1 wherein said drug comprises amiloride, hydrochlorothiazole, amiloride and hydrochlorothiazide, carbidopa, levodopa, cefoxitin, cefmetzole, cyclobenzaprine, diflunisal, iodomethacin, sulindac, timolol, (-)-1-(cyclopropylmethyl)4-[3-(trifluoromethylthio)-5H-dibenzo(a,d)-cyclohepten-5-ylidene]-piperidine hydrochloride, N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-L-proline maleate, (+)10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine oxalate, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid, 3-fluoro-D-alanine and D-4(1-methyl-3-oxo-1-butenylamino)-3-isoxazolidinone sodium salt hemihydrate, L-N-(2-oxo-piperidin-6-ylcarbonyl)-histidyl-L-thiazolidine-4-carboxamide, N-formimidoyl thienamycin monohydrate, (6,7-dichloro-2-methyl-2-phenyl-1-oxo-5-indanyloxy) acetic acid, ibuprofen, naproxen, 5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acid, phenylbutazone, dexamethasone, prednisolone, clonidine, propranolol, diazepam, chlordiazepoxide, furosemide, cephamandole, nalidixic acid, amoxicillin, haloperidol, captopril or Ara-C.
Claim 6
Dependent Claim
10 words
The method of claim 1 wherein said drug comprises cefoxitin.
Claim 7
Dependent Claim
10 words
The method of claim 1 wherein said drug comprises gentamycin.
Claim 8
Dependent Claim
10 words
The method of claim 1 wherein said drug comprises 4-amino-1B-D-arabinofuranosyl-2-(1H)-pyrimidinone.
Claim 9
Dependent Claim
24 words
The method of claim 1 wherein said adjuvant comprises: glyoxylic acid or a pharmaceutically acceptable acid addition salt thereof, phenyl glyoxal or methyl glyoxal.
Claim 10
Dependent Claim
147 words
A rectally or orally administered drug form comprising a therapeutically effective dosage amount of a drug capable of being absorbed into the bloodstream from the gastrointestinal compartment said drug comprising an antibiotic, xanthine, anticancer agent, polypeptide, antiarthritic, cardiovascular agent, antidiabetic, antiulcer, antifungal, antinauseant, sedative, diuretic, antihypertensive, anti-inflammatory, anthelmintic, antiviral agent, radio-opaque and radionuclide diagnostic agent, polynucleotide, or an anti-Parkison agent and an α-keto aldehyde of the formula: ##STR4## wherein R is hydroxy, lower alkyl (C 1-5 ), phenyl, or substituted phenyl wherein the substituents are halo, lower alkyl (C 1-5 ), hydroxy or a pharmaceutically acceptable acid addition salt thereof as adjuvant, said adjuvant being present in said drug form in a sufficient amount to be effective in enhancing the absorption of said drug from said gastrointestinal compartment into the bloodstream and wherein the percentage of drug to drug plus adjuvant is 5% to 50% by weight.
Claim 11
Dependent Claim
147 words
A rectally or orally administered drug form comprising a therapeutically effective dosage amount of a drug capable of being absorbed into the bloodstream from the gastrointestinal compartment said drug comprising an antibiotic, xanthine, anticancer agent, polypeptide, antiarthritic, cardiovascular agent, antidiabetic, antiulcer, antifungal, antinauseant, sedative, diuretic, antihypertensive, anti-inflammatory, anthelmintic, antiviral agent, radio-opaque and radionuclide diagnostic agent, polynucleotide, or an anti-Parkison agent and an α-keto aldehyde of the formula: ##STR4## wherein R is hydroxy, lower alkyl (C 1-5 ), phenyl, or substituted phenyl wherein the substituents are halo, lower alkyl (C 1-5 ), hydroxy or a pharmaceutically acceptable acid addition salt thereof as adjuvant, said adjuvant being present in said drug form in a sufficient amount to be effective in enhancing the absorption of said drug from said gastrointestinal compartment into the bloodstream and wherein the percentage of drug to drug plus adjuvant is 5% to 50% by weight.
Claim 12
Dependent Claim
23 words
The drug form of claim 9 wherein said adjuvant comprises: glyoxylic acid or a pharmaceutically acceptable acid addition salt thereof, phenylglyoxal or methylglyoxal.
Claim 13
Dependent Claim
65 words
The drug form of claim 9 wherein said drug comprises amiloride, hydrochlorothiazide, amiloride and hydrochlorothiazide, carbidopa, levodopa, cefoxitin, cefmetzole, cyclobenzaprine, diflunisal, indomethacin, sulindac, timolol, (-)-1-(cyclopropylmethyl) 4-[3-(trifluoromethylthio)5H-dibenzo(a,d)cyclohepten-5-ylidene]-piperidine hydrochloride, N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-L-proline maleate, (+)10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine oxalate, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid, 3-fluoro-D-alanine and D-4-(1-methyl-3-oxo-1-butenylamino)-3-isoxazolidinone sodium salt hemihydrate, L-N-(2-oxopiperidin-6-ylcarbonyl)-histidyl-L-thiazolidine-4-carboxamide, N-formimidoyl thienamycin monohydrate, (6,7-dichloro-2-methyl-2-phenyl-1-oxo-5-indanyloxy)acetic acid, ibuprofen, naproxen, 5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acid, phenylbutazone, dexamethasone, prednisolone, clonidine, propranolol, diazepam, chlordiazepoxide, furosemide, cephamandole, nalidixic acid, amoxicillin, haloperidol, captopril or 4-amino-1β-D-arabinofuranosyl-2-(1H)-pyrimidnone.
Claim 14
Dependent Claim
11 words
The drug form of claim 9 wherein said drug comprises cefoxitin.
Claim 15
Dependent Claim
11 words
The drug form of claim 9 wherein said drug comprises gentamycin.
Claim 16
Dependent Claim
11 words
The drug form of claim 9 wherein said drug comprises 4-amino-1β-D-arabinofuranosyl-2-(1H)-pyrimidinone.
Claim 17
Dependent Claim
25 words
The drug form of claim 9 wherein said adjuvant comprises: glyoxylic acid or a pharmaceutically acceptable acid addition salt thereof, phenyl glyoxal or methyl glyoxal.
Claim 18
Dependent Claim
10 words
The method of claim 1 wherein said drug comprises Cyclo-(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe).
Claim 19
Dependent Claim
11 words
The drug form of claim 9 wherein said drug comprises Cyclo-(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe).
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-04-03 | 1987-10-03 | 1988-04-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-04-03 | 1991-10-03 | 1992-04-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-04-03 | 1995-10-03 | 1996-04-03 | $7700.00 | Window Closed / Lapsed |